CorMedix Inc. — Director's Dealing 2013

Mar 22, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CorMedix Inc. (CRMD)
CIK: 0001410098
Period of Report: 2013-03-20

Reporting Person: Gelbfish Gary A. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-03-20	Stock Option (right to buy)	$0.9	A	50000	Acquired	2023-03-20	Common Stock, $0.001 par value per share (50000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, $0.001 par value per share	188668	Direct
Common Stock, $0.001 par value per share	70872	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$0.68	2022-12-05	Common Stock, $0.001 par value per share (70000)	70000	Direct
Senior Convertible Note (convertible into Common Stock)	$0.35	2013-09-20	Common Stock, $0.001 par value per share (285714)	285714	Direct
Warrant (right to purchase Comm Stock)	$0.4	2017-09-20	Common Stock, $0.001 par value per share (250000)	250000	Direct
Stock Option (right to buy)	$0.29	2022-01-06	Common Stock, $0.001 par value per share (30000)	30000	Direct
Stock Option (right to buy)	$2.1	2021-01-14	Common Stock, $0.001 par value per share (30000)	30000	Direct
Stock Option (right to buy)	$3.125	2020-03-30	Common Stock, $0.001 par value per share (20000)	20000	Direct
8% Noteholder Warrants	$3.4375	2016-10-29	Common Stock, $0.001 par value per share (67200)	67200	Direct
8% Noteholder Warrants	$3.4375	2016-10-29	Common Stock, $0.001 par value per share (28800)	28800	Indirect

Footnotes

F1: These options vest quarterly over two years beginning June 30, 2013.

F2: These options vest as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, if the CE Mark approval is obtained on or before June 30, 2013, and (b) fifty percent (50%) on December 31, 2013.

F3: The options vest in full on the first anniversary of the date of grant.

F4: Includes (i) 94,496 shares of our common stock held jointly by Dr. Gelbfish and his wife, (ii) 70,872 shares of our common stock held by Dr. Gelbfish as custodian for certain of his children, and (iii) 70,872 shares of our common stock held by Landmark Foundation, of which Dr. Gelbfish and his wife are trustees.

F5: Held by Landmark Foundation, of which Dr. Gelbfish and his wife are trustees.

F6: These options vest on January 14, 2012.

F7: These options vest as follows: 1/3 on March 30, 2010; an additional 1/3 on March 30, 2011; and the remaining 1/3 on March 30, 2012.

F8: These warrants will become exercisable upon the consummation of the Company's initial public offering.

F9: Includes 8% Noteholder Warrants held by Dr. Gelbfish and his wife jointly, that are exercisable for 38,400 shares of common stock, and 8% Noteholder Warrants held by Dr. Gelbfish as custodian for certain of his children that are exercisable for 28,800 shares of common stock.